Observational study / 2014
Body mass index at study entry was not significantly linked to failure-free or overall survival in patients with DLBCL, HL, or FL.
Researchers analyzed the association between baseline BMI categories and survival outcomes in three phase III clinical trials of lymphoma patients. Across patients with DLBCL, HL, and FL, BMI was not associated with failure-free survival (P = 0.89, 0.30, and 0.40, respectively) or overall survival (P = 0.64, 0.67, and 0.09, respectively). Associations remained non-significant after adjusting for clinical factors in Cox models, and a subset analysis of males with DLBCL treated with R-CHOP showed no differences in FFS (P = 0.48) or OS (P = 0.58).
Shows an association, not proof of cause and effect.
- Study type
- Secondary analysis of 3 phase III randomized controlled trials
- Who was studied
- 537 patients with DLBCL, 730 with HL, and 282 with FL
- What was measured
- Failure-free survival (FFS) and overall survival (OS)
THE PAPER
The role of body mass index in survival outcome for lymphoma patients: US intergroup experience.
Hong F, Habermann TM, Gordon LI, Hochster H, Gascoyne RD, Morrison VA, Fisher RI, Bartlett NL, Stiff PJ, Cheson BD, Crump M, Horning SJ, Kahl BS. Ann Oncol, 2014.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.